China
克睿基因 Cure Genetics, with the slogan Benifiting Lives with Genetic Engineering, is an innovative gene therapy company focused on the application development of viral delivery systems and gene editing systems. Addressing the clinical needs of complex genetic diseases and hard-to-treat tumors, the company actively engages in international collaborations to build a breakthrough product pipeline, aiming to set a benchmark in the global gene therapy sector.
Founded in 2016 and headquartered in China, the company is strategically located in Suzhou Industrial Park, where it assembles core talent from diverse domestic and international fields. Centered around the AAV viral delivery system and CRISPR gene editing system, Cure Genetics has established a comprehensive differentiated platform, bolstered by proprietary core intellectual property. Its scientific advisory board comprises renowned scientists and executives from multinational pharma companies, laying a robust foundation for technology commercialization.
The company's recent financial progress is marked by a $9.00M Series B investment on March 28, 2024, led by Qiming Venture Partners, signaling strong investor confidence in its growth trajectory and innovative capabilities within the Biotechnology and Health Care industries.
